Mr. Chen has extensive experiences in therapeutics research and development, regulatory strategy and company operation. He has over 20 years’ experience in regenerative medicine, cell therapy, biologics and small molecule therapeutics products R&D covering CNS, psychiatric, cancers, cardiovascular, pulmonary, renal, hepatic, autoimmune, ophthalmic and metabolic diseases.  Prior to joining Maxpro ventures, Mr. Chen was VP and Acting COO of SyneuRx International Inc. (Taiwan). Prior to that, he was VP of Pharmacology at Meridigene (Taiwan). Before returning to Taiwan, Mr. Chen spent 14 years in biotech companies in the US including Celgene as Sr. Principal Scientist, Amcyte as group leader and VivoRx as Sr. Scientist. Through his carrier in industry, Mr. Chen was instrumental to many successful IND submissions to regulatory authorities in the US, Canada and Taiwan. Among them, two were granted Breakthrough Therapy Designation (BTD) by the US FDA. Prior to his career in biotech industry, Mr. Chen was a senior research fellow (faculty rank) in Biology Division at California Institute of Technology. Currently, Mr. Chen is also an ad hoc reviewer of Stem Cells Translational Medicine and a supervisor of ReVasgen Inc.

Mr. Chen received his Ph.D. in Microbiology and Molecular Genetics from Rutgers, The State University of New Jersey and The University of Medicine and Dentistry of New Jersey. He did his postdoctoral training in neuroscience at California Institute of Technology.

Mr. Chung has been a professional venture capitalist since year 2000. With a background in pharmaceutical science, Mr. Chung has been involved in cutting-edge therapeutic start-ups and identifying potential drug discovery projects originated from research institutes. In the course of his experience, he has made successful investment in 30 life science ventures with exit through IPO or M&A. His past investment included Pharmasset, Peninsula, Cerexa, Tanox, Corgentech, Santarus, Anchen, Epitomics, Renovis, Xanthus, PharmaEngine, TaiRx, and TaiMed. Present board memberships include Innopharmax, Tekho, Intech, and Jaguar Technology.

Prior to MaxPro, Mr. Chung was VP & Managing Director of TaiAn Technologies, the largest biotech venture capital in Taiwan. Previous to that, Francis held executive positions at TTY Biopharm, CDIB Bioscience Ventures, Fortune Ventures, and SynpacKingdom Pharmaceuticals. He was also involved in drug discovery and development at Pfizer and Eli-Lilly.

Mr. Chung received his B.S. in Chemistry from National Taiwan University, his Ph.D. in  Pharmaceutics from University of Iowa, and his MBA from National Taiwan University.

Mr. Chen, with backgrounds in biotechnology and venture capital, is a founder of Maxpro Ventures. Mr. Chen’s professional expertise in asset management has led to his successful execution of more than 60 private equity investment transactions in the USA and the Asia-Pacific region. His past investments included Acepodia, SyneuRx, GenScript, JHL Biotech, Foresee, HEC Pharma, and ACT Genomics Holdings, to list a few.

Prior to founding Maxpro Ventures, Mr. Chen was Senior Director of Integral Group. He was jointly in charge of Integral’s Asian transaction process, managed its Shanghai branch, and served as a board member of multiple portfolio companies such as Generon Corporation, FusionVax, Inc., BioLite, Inc., and Flora International Group Co., Ltd.. From 1999 to 2012, Mr. Chen held various senior management positions in the investment division at Central Investment Holdings. During that period, his successful investments included Tanox and Biopure, to name just a few. In 2002, a significant transaction that Mr. Chen had made was the acquisition of SEEDNet by New Century InfoComm Tech. He also served on several corporate boards, such as Concord Fund Company, Singfor Life Insurance Company, and CTCI Corporation.

Mr. Chen received an MBA from Syracuse University and an MS from the University of Minnesota.

Ms. Hong joined Maxpro in 2021. She has strong accounting and financial background. Prior to Maxpro, Ms. Hong was the chief accountant of Integral Shanghai. During the 12 years tenure with Integral Group, she developed herself to be an expert in many facets in investment including accounting operations, fund raising, investing and project management. She led and participated in many investment projects, including Shandong Buchang Pharmaceuticals Co., Meituan, Dianping, Benlai, Generon Corporation, Golden Crown Energy, covering biotech, o2o, new energy, big consumption and other fields.

Ms. Hong received a BA degree in economics from Shandong University and an MS degree in finance from Fudan University.

Mr. Zhao joined Maxpro in 2019 with a strong financial background. Prior to joining Maxpro, Mr. Zhao was an Investment Analyst at Brother Enterprises Holding with a focus on M&A and business strategies. He helped Brother set up new business modules in active pharmaceutical ingredients and chemical drugs.

Mr. Zhao received a M.S. in Finance from Ohio State University, a B.S. in Finance and a second B.S. in International Business from Marquette University.

Ms. Hsu has over 15 years of financial institutions and private equity experience, including DnB, Jardine Matheson and SGO PE Fund. During the years, she focused on the accounting operations and project management. She also has participated in the fundraising plan for start-up companies, one of them is Meiya app in Pre-A round.

Ms. Hsu received a BA degree in Accounting from Fu Jen University.

Mr. Yang joined Maxpro in 2021 with a strong analytical and quantitative background. In the course of his Ph.D. studies, he worked closely with one of the major banks in the United States and helped them optimize their business strategy by developing various mathematical models.

Mr. Yang received his Ph.D. degree in Economics from Carnegie Mellon University and BA degrees in both Mathematical Science and Economics.

Ms. Lee comes with quality, regulatory and project evaluation experiences in pharmaceuticals along with extensive biomedical research knowledge during her academic training.
Prior to joining Maxpro ventures, Ms. Lee served as quality and regulatory affairs for JHL biotech (Eden Biologics) and Lumosa therapeutics (for 9 years).

Ms. Lee received her PhD in Biochemistry from Texas A&M University and pursued postdoc training at the world-leading MD Anderson cancer center. During the postdoc training, she also obtained a certificate of biotech pharmaceuticals development management from Rice University MBA Alliance program.

Mr. Huang joined Maxpro in 2022 with legal and financial backgrounds. He is a lawyer dual qualified in California, the United States, and New South Wales, Australia. He is also a Taiwan Licensed Certified Securities Investment Analyst. Prior to joining Maxpro, Mr. Huang respectively served as associate for FinTech Taiwan, specialist for Taiwan’s Financial Supervisory Commission and corporate banking relationship manager for Cathay United Bank. Mr. Huang has three years’
experience in banking and finance.

Mr. Huang earned his JD degree from University of New South Wales (UNSW), his LL.M. degree from University of Pennsylvania (UPenn) and his MBA degree from National Taiwan University. His research thesis A Roadmap for Regulating RegTech in the Financial Sector at UNSW is awarded the distinction. When studying at Upenn, he was a member of Wharton FinTech Club and served as pro bono legal assistant for Military Assistance Project.

Mr. Lin is a US CPA who worked for KPMG US for three years as a Senior Associate in the Audit practice responsible for auditing clients in Private Equity, Real Estate Management/Development, and Consumer Goods industries. At KPMG, he gained valuable experience in practicing US GAAP, establishing and testing internal controls, and performing financial analyses/due diligence to identify potential risk areas in companies’ financial statements. After leaving public accounting, Mr. Lin worked as a mortgage banker and financial analyst.

Mr. Lin received his BA in Accounting and Finance from the University of Washington, Seattle.

Ms. Hwang has diverse backgrounds in banking and investments. She started her career as a management trainee at Standard Chartered Bank and launched several IPO funds & equity/ETFs as an investment product manager in wealth management division. She also has experiences in managing corporate actions and implementing cross-border investment App.

Prior to joining Maxpro, Ms. Hwang worked at Walsin Lihwa Corporation for a joint venture in Indonesia.

Ms. Hwang received an MBA from Columbia University and a BSc from National Chengchi University.

Miss Huang joined Maxpro in 2022 with an advertising background. Prior to joining Maxpro she worked at Ogilvy, with top FMCG clients such as Kimberly Clark, Pernod Ricard, and Nike.

Miss Huang received her BS in Business and Management from the University of London.

Ms. Wang joined Maxpro in 2022 with legal background. Prior to joining Maxpro, Ms. Wang worked at KKBOX Group as corporate legal in Taiwan and a law firm in Boston, Massachusetts.She has experience in handling various kinds of B2B and B2C cases, and assisted in corporate governance.

Ms. Wang received LL.M. degree from Boston University and LL.B. degree from Soochow University

Mr. Wang joined Maxpro in 2022 with a background in Biomedical Sciences. He has extensive research experiences in biochemistry, molecular biology, cell biology, cancer biology and neuroscience.

Prior to joining Maxpro Ventures, he worked as a senior R&D engineer at GeneReach Biotechnology Corp. for the development of diagnostic assays.

Mr. Wang received his PhD degree in Integrative Molecular and Biomedical Sciences from Baylor College of Medicine and pursued post-doctoral training in neuroscience at University of California, Davis.

Mr. Zhao joined Maxpro in 2019 with a strong financial background. Prior to joining Maxpro, Mr. Zhao was an Investment Analyst at Brother Enterprises Holding with a focus on M&A and business strategies. He helped Brother set up new business modules in active pharmaceutical ingredients and chemical drugs.

Mr. Zhao received a M.S. in Finance from Ohio State University, a B.S. in Finance and a second B.S. in International Business from Marquette University.

Ms. Liu joined Maxpro in 2023 with a background in finance. Prior to joining Maxpro, she gained extensive experience as an intern at Hung Tse Investment, where she conducted comprehensive research on individual stocks and industries. Furthermore, during her other internships, she demonstrated exceptional proficiency in developing and backtesting trading strategies.

Ms. Liu received a M.S. degree in Quantitative Finance from National Tsing Hua University and a B.S. degree in Economics from National Chi Nan University.